… The development of 177 Lu-labeled small ligands for prostate cancer … prostate-specific
membrane antigen (PSMA) ligands, 177 Lu-PSMA RLT was introduced by the German Cancer …

… 177 Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) for
metastatic castration-resistant prostate cancer (… safety data on 177 Lu-PSMA RLT for mCRPC …

… PSMA PET/CT was not prognostic. Accordingly, we infer in this setting of PSMA-avid
advanced prostate cancer… on patient outcome than the volume of PSMA-avid disease which is …

… To our knowledge, this is the largest cohort analyzed in a multicenter approach for 177 Lu-PSMA-617
RLT of prostate cancer. There was no therapy-related death after 248 therapy …

… therapy in patients with relapsed or metastatic prostate cancer. The aim of this study … of 177
Lu-PSMA-617 in a large cohort of patients with metastatic castration-resistant prostate cancer …

… 177 Lu-PSMA (prostate specific membrane antigen) therapy for metastatic castration-resistant
prostate cancer … Lu-PSMA therapy efficacy was assessed by using prospective trials, meta-…

… -resistant prostate cancer (mCRPC) 1 . However, the treatment of mCRPC patients with
177 Lu-PSMA-617 (Lu-PSMA) achieves biochemical response (> 50% decline of prostate-…

… Radioligand therapies such as lutetium-177 ( 177 Lu)–PSMA-617 can target prostate cancer
cells while sparing most normal tissues in patients who have been selected with the use of …

… further refined in tumor-targeting … 177 Lu-PSMA-617 in patients with advanced mCRPC
resistant to or with contraindications to other conventional therapies and PSMA-positive tumor …

… treatment with [ 177 Lu]-PSMA-617 has high response rates, low toxic effects, and reduction
of pain in men with metastatic castration-resistant prostate cancer who have progressed …